Nephrolithiasis — Written Clinical Reasoning

Part A — Diagnosis and pathophysiology

Diagnosis

The diagnosis is recurrent calcium oxalate nephrolithiasis secondary to enteric hyperoxaluria from Crohn disease with prior terminal ileal resection. The four stone episodes in six years, the documented hyperoxaluria (0.9 mmol per day, well above the upper limit of 0.5), the hypocitraturia (1.2 mmol per day, below the lower limit of 2.5 for men), and the low urine volume (1.2 L per day) collectively explain the recurrent stone formation. The normal serum calcium and PTH exclude primary hyperparathyroidism as a contributing factor. [1]

Pathophysiology of enteric hyperoxaluria

The mechanism is well established [1]. In patients with fat malabsorption from Crohn disease (especially after ileal resection), unabsorbed long-chain fatty acids reach the colon and saponify dietary calcium — that is, calcium binds to fatty acids instead of oxalate. This leaves free oxalate available for absorption in the colon, where it enters the portal circulation and is excreted by the kidney. The result is hyperoxaluria, which drives calcium oxalate supersaturation and stone formation.

Two additional factors compound the problem in this patient: [1]

1. Hypocitraturia from chronic diarrhoea — citrate is the main inhibitor of calcium crystal growth, and intestinal bicarbonate loss from chronic diarrhoea produces a metabolic acidosis that increases renal citrate reabsorption, reducing urinary citrate [1].
2. Low urine volume from chronic diarrhoea and inadequate fluid replacement — concentrated urine increases supersaturation of all stone-forming solutes.

The patient's current low-calcium diet (500 mg per day) is actively harmful — it worsens enteric hyperoxaluria by leaving even more free oxalate available for colonic absorption [2].

Part B — Metabolic evaluation

What has been done well

The 24-hour urine collection is the cornerstone of metabolic evaluation in recurrent stone formers and has correctly identified the three driving abnormalities (hyperoxaluria, hypocitraturia, low volume). The serum calcium and PTH have excluded hyperparathyroidism. The stone analysis (calcium oxalate) is consistent with the metabolic profile. [1]

What I would add

I would obtain a second 24-hour urine collection on a different day to confirm the abnormalities (single collections can be misleading). I would also check:

• Serum bicarbonate and potassium — to assess for the metabolic acidosis that accompanies chronic diarrhoea and drives hypocitraturia
• Serum urate — to exclude concurrent hyperuricosuria
• eGFR — to assess for any renal function impairment from recurrent obstruction or CKD
• Urine culture — to exclude subclinical urinary tract infection (especially relevant in a patient with recurrent stones and altered bowel anatomy) [1]

Part C — Integrated prevention plan

Dietary modification

Fluid intake — the single most important intervention. The target is a urine output above 2.5 L per day, which given his chronic diarrhoeal losses will require an intake of at least 3 to 4 L per day. I would counsel him to drink consistently throughout the day and to monitor urine colour (aiming for pale, dilute urine). Given the ileostomy or diarrhoea, oral rehydration solution may be needed to maintain hydration without worsening diarrhoea [5].

Calcium intake — the current low-calcium diet (500 mg per day) must be corrected. Calcium should be increased to 1000 to 1200 mg per day, taken with meals so that it binds intestinal oxalate and prevents its absorption. The Borghi trial proved that normal calcium intake with reduced sodium and protein halves stone recurrence compared with a low-calcium diet [2]. In enteric hyperoxaluria, oral calcium supplementation with meals is particularly important because it directly binds the free oxalate that would otherwise be absorbed.

Low-oxalate diet — restrict spinach, rhubarb, nuts, chocolate, tea, and beetroot. This is especially relevant in enteric hyperoxaluria where the intestine is primed to absorb oxalate. [1]

Low-fat diet — reducing dietary fat reduces the fatty acids available to saponify calcium, leaving more calcium to bind oxalate in the gut. This is specific to enteric hyperoxaluria and would not be necessary in idiopathic stone formers. [1]

Pharmacotherapy

Potassium citrate — indicated for the documented hypocitraturia. It alkalinises the urine and increases urinary citrate, which complexes calcium and inhibits crystal growth. The starting dose is 10 mEq twice daily, titrated to a urine pH of 6.5 to 7.0 and a citrate level in the normal range. I would monitor serum potassium, especially in the setting of chronic diarrhoea which can cause potassium wasting. Importantly, potassium citrate also corrects the metabolic acidosis from chronic diarrhoea, which addresses one of the root causes of the hypocitraturia [5].

Calcium supplements with meals — calcium carbonate 500 to 1000 mg with each main meal, to bind intestinal oxalate. This is distinct from calcium supplementation for bone health (which is taken between meals); the goal here is intraluminal oxalate binding, so the calcium must be taken with food. [1]

Cholestyramine — a bile acid sequestrant that binds bile acids in the gut, reducing the bile acid-mediated increase in colonic permeability to oxalate. It is considered for refractory enteric hyperoxaluria when dietary measures and calcium supplementation are insufficient. [1]

Thiazide diuretics — NOT indicated in this patient, who has normal urinary calcium. Thiazides are for hypercalciuria; prescribing them here would not address the primary abnormality (hyperoxaluria) and could worsen the volume depletion from chronic diarrhoea. [1]

Treatment of the underlying bowel disease

Optimising the Crohn disease management to reduce diarrhoea and fat malabsorption is fundamental. This may involve escalation of immunosuppressive therapy, anti-diarrhoeal agents (loperamide where appropriate), and nutritional support. If the patient has an ileostomy, the high-output stoma may need specific management (codeine, loperamide, octreotide) to reduce fluid and electrolyte losses. [1]

Part D — Surgical considerations and acute management

Acute renal colic

If the patient presents with acute colic, NSAIDs (diclofenac 75 mg IM) are first-line analgesia. However, in a patient with chronic diarrhoea and potential volume depletion, I would check renal function before NSAIDs and avoid them if the eGFR is below 30 or if the patient is significantly dehydrated. Non-contrast CT KUB is the imaging of choice to confirm the stone, assess size and location, and identify hydronephrosis. For a stone below 5 mm, expectant management is appropriate. For a stone 5 to 10 mm, medical expulsive therapy with tamsulosin may be considered — the SUSPEND trial showed no overall benefit, but the Hollingsworth meta-analysis suggested modest benefit for larger distal ureteric stones [4][6]. For stones above 10 mm, intervention is needed.

Surgical intervention

For this patient with recurrent stones, the choice of intervention depends on stone size and location:

• ESWL — for stones below 2 cm in the renal pelvis or upper ureter
• Ureteroscopy with holmium laser — for ureteric stones and renal stones, especially lower pole; this is preferred over ESWL for hard stones
• PCNL — for stones above 2 cm or staghorn calculi [1]

Obstructive pyelonephritis

The critical emergency to recognise is obstructive pyelonephritis — an infected obstructed system. If this patient presents with fever, rigors, and an obstructing stone, urgent decompression (ureteric stent or percutaneous nephrostomy) is mandatory within hours, with antibiotics alone being insufficient. [1]

Part E — Long-term follow-up and surveillance

I would arrange:

• Annual 24-hour urine re-evaluation to confirm that the urinary biochemistry has normalised (oxalate below 0.5 mmol/day, citrate above 2.5 mmol/day, volume above 2.5 L/day) — the goal is not just prescribing therapy but confirming it works
• Annual bloods — eGFR, electrolytes, bicarbonate, calcium, and urate
• Bone density (DEXA) — patients with chronic malabsorption and hypocitraturia are at risk of osteoporosis from malabsorption and metabolic acidosis
• Urology follow-up — for surveillance of existing stones and management of new episodes [1]

The patient should be counselled that with targeted therapy, the recurrence rate can be reduced by 50 to 80 per cent, but that this requires sustained adherence to the fluid, dietary, and pharmacological regimen. [1]

Part F — Key discriminating points for the exam

The key discriminating points for this case:

1. Enteric hyperoxaluria (not idiopathic) — the mechanism is fat malabsorption freeing oxalate for colonic absorption, and the treatment includes calcium with meals (to bind oxalate), low-fat diet, and cholestyramine, which are specific to enteric hyperoxaluria.
2. The low-calcium diet is wrong — normal calcium intake with meals is the correct advice, proven by the Borghi trial [2].
3. Potassium citrate addresses both the hypocitraturia and the metabolic acidosis from chronic diarrhoea.
4. Thiazides are NOT indicated — the calcium is normal; prescribing thiazides for non-hypercalciuric patients is a common exam error.
5. The 24-hour urine is the key investigation — it identifies the specific metabolic abnormalities that guide targeted therapy, rather than empiric treatment.